Health1 min read

Lilly’s triple-G drug beats Ozempic in head-to-head study

By · Via STAT Health · Published by Everything Blog

In short

Eli Lilly announced that its investigational drug retatrutide outperformed Novo Nordisk’s Ozempic in a large diabetes study. According to the company, the triple-G drug proved more effective at both lowering blood sugar and reducing weight. The findings come from a head-to-head comparison between the two treatments.

Key points

  • Eli Lilly announced that its investigational drug retatrutide outperformed Novo Nordisk’s…: Eli Lilly announced that its investigational drug retatrutide outperformed Novo Nordisk’s Ozempic in a large diabetes study.
  • According to the company, the triple-G drug proved more effective at both lowering blood…: According to the company, the triple-G drug proved more effective at both lowering blood sugar and reducing weight.
  • The findings come from a head-to-head comparison between the two treatments.: The findings come from a head-to-head comparison between the two treatments.

Sources checked by our analysis pipeline: 1

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’ve got lots of news today to get into.

Lilly’s triple-G drug beats Ozempic in head-to-head study

Eli Lilly said this morning that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Original source: www.statnews.com

Health